vs
Side-by-side financial comparison of Stoke Therapeutics, Inc. (STOK) and SMITH & WESSON BRANDS, INC. (SWBI). Click either name above to swap in a different company.
Stoke Therapeutics, Inc. is the larger business by last-quarter revenue ($158.6M vs $124.7M, roughly 1.3× SMITH & WESSON BRANDS, INC.). Stoke Therapeutics, Inc. runs the higher net margin — 71.2% vs 1.5%, a 69.6% gap on every dollar of revenue. On growth, Stoke Therapeutics, Inc. posted the faster year-over-year revenue change (3661.1% vs -3.9%). Stoke Therapeutics, Inc. produced more free cash flow last quarter ($131.7M vs $16.3M).
Stoke Therapeutics, Inc. is a clinical-stage biotechnology company developing innovative RNA-targeted therapies for severe rare genetic diseases. Its lead candidates address unmet needs for Dravet syndrome, a rare epilepsy, and other neurological monogenic disorders, serving patients across North America and global markets.
Smith & Wesson Brands, Inc. (S&W) is an American firearm manufacturer headquartered in Maryville, Tennessee, United States.
STOK vs SWBI — Head-to-Head
Income Statement — Q1 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $158.6M | $124.7M |
| Net Profit | $112.9M | $1.9M |
| Gross Margin | — | 24.3% |
| Operating Margin | 70.2% | 3.3% |
| Net Margin | 71.2% | 1.5% |
| Revenue YoY | 3661.1% | -3.9% |
| Net Profit YoY | 528.0% | -53.6% |
| EPS (diluted) | $1.90 | $0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $124.7M | ||
| Q3 25 | — | $85.1M | ||
| Q2 25 | — | $140.8M | ||
| Q1 25 | $158.6M | $115.9M | ||
| Q4 24 | $22.6M | $129.7M | ||
| Q3 24 | — | $88.3M | ||
| Q2 24 | — | $159.1M | ||
| Q1 24 | — | $137.5M |
| Q4 25 | — | $1.9M | ||
| Q3 25 | — | $-3.4M | ||
| Q2 25 | — | $8.6M | ||
| Q1 25 | $112.9M | $2.1M | ||
| Q4 24 | $-10.5M | $4.5M | ||
| Q3 24 | — | $-1.9M | ||
| Q2 24 | — | $27.9M | ||
| Q1 24 | — | $7.9M |
| Q4 25 | — | 24.3% | ||
| Q3 25 | — | 25.9% | ||
| Q2 25 | — | 28.8% | ||
| Q1 25 | — | 24.1% | ||
| Q4 24 | — | 26.6% | ||
| Q3 24 | — | 27.4% | ||
| Q2 24 | — | 35.5% | ||
| Q1 24 | — | 28.7% |
| Q4 25 | — | 3.3% | ||
| Q3 25 | — | -3.5% | ||
| Q2 25 | — | 9.3% | ||
| Q1 25 | 70.2% | 4.1% | ||
| Q4 24 | -60.4% | 5.8% | ||
| Q3 24 | — | -1.7% | ||
| Q2 24 | — | 17.4% | ||
| Q1 24 | — | 8.2% |
| Q4 25 | — | 1.5% | ||
| Q3 25 | — | -4.0% | ||
| Q2 25 | — | 6.1% | ||
| Q1 25 | 71.2% | 1.8% | ||
| Q4 24 | -46.4% | 3.5% | ||
| Q3 24 | — | -2.1% | ||
| Q2 24 | — | 17.5% | ||
| Q1 24 | — | 5.7% |
| Q4 25 | — | $0.04 | ||
| Q3 25 | — | $-0.08 | ||
| Q2 25 | — | $0.19 | ||
| Q1 25 | $1.90 | $0.05 | ||
| Q4 24 | $-0.15 | $0.10 | ||
| Q3 24 | — | $-0.04 | ||
| Q2 24 | — | $0.60 | ||
| Q1 24 | — | $0.17 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $274.8M | $22.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $350.1M | $363.2M |
| Total Assets | $406.9M | $548.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $22.4M | ||
| Q3 25 | — | $18.0M | ||
| Q2 25 | — | $25.2M | ||
| Q1 25 | $274.8M | $26.7M | ||
| Q4 24 | $128.0M | $39.1M | ||
| Q3 24 | — | $35.5M | ||
| Q2 24 | — | $60.8M | ||
| Q1 24 | — | $47.4M |
| Q4 25 | — | $363.2M | ||
| Q3 25 | — | $364.4M | ||
| Q2 25 | — | $372.5M | ||
| Q1 25 | $350.1M | $366.9M | ||
| Q4 24 | $229.0M | $371.5M | ||
| Q3 24 | — | $380.0M | ||
| Q2 24 | — | $399.9M | ||
| Q1 24 | — | $376.4M |
| Q4 25 | — | $548.6M | ||
| Q3 25 | — | $554.6M | ||
| Q2 25 | — | $559.6M | ||
| Q1 25 | $406.9M | $578.9M | ||
| Q4 24 | $271.6M | $587.4M | ||
| Q3 24 | — | $571.3M | ||
| Q2 24 | — | $577.4M | ||
| Q1 24 | — | $570.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $131.8M | $27.3M |
| Free Cash FlowOCF − Capex | $131.7M | $16.3M |
| FCF MarginFCF / Revenue | 83.0% | 13.1% |
| Capex IntensityCapex / Revenue | 0.1% | 8.8% |
| Cash ConversionOCF / Net Profit | 1.17× | 14.22× |
| TTM Free Cash FlowTrailing 4 quarters | — | $21.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $27.3M | ||
| Q3 25 | — | $-8.1M | ||
| Q2 25 | — | $40.8M | ||
| Q1 25 | $131.8M | $-9.8M | ||
| Q4 24 | $-23.2M | $-7.4M | ||
| Q3 24 | — | $-30.8M | ||
| Q2 24 | — | $43.7M | ||
| Q1 24 | — | $25.2M |
| Q4 25 | — | $16.3M | ||
| Q3 25 | — | $-12.4M | ||
| Q2 25 | — | $33.5M | ||
| Q1 25 | $131.7M | $-16.1M | ||
| Q4 24 | $-23.2M | $-10.7M | ||
| Q3 24 | — | $-35.5M | ||
| Q2 24 | — | $38.2M | ||
| Q1 24 | — | $7.0M |
| Q4 25 | — | 13.1% | ||
| Q3 25 | — | -14.6% | ||
| Q2 25 | — | 23.8% | ||
| Q1 25 | 83.0% | -13.9% | ||
| Q4 24 | -102.7% | -8.3% | ||
| Q3 24 | — | -40.2% | ||
| Q2 24 | — | 24.0% | ||
| Q1 24 | — | 5.1% |
| Q4 25 | — | 8.8% | ||
| Q3 25 | — | 5.0% | ||
| Q2 25 | — | 5.2% | ||
| Q1 25 | 0.1% | 5.4% | ||
| Q4 24 | 0.2% | 2.5% | ||
| Q3 24 | — | 5.3% | ||
| Q2 24 | — | 3.5% | ||
| Q1 24 | — | 13.2% |
| Q4 25 | — | 14.22× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 4.73× | ||
| Q1 25 | 1.17× | -4.68× | ||
| Q4 24 | — | -1.63× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 1.57× | ||
| Q1 24 | — | 3.20× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
